Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
作者信息
Ko Heidi, Previs Rebecca A, Strickland Kyle C, Klein Jonathan, Caveney Brian, Chiruzzi Chiara, Eisenberg Marcia, Severson Eric A, Ramkissoon Shakti, Saini Kamal S
机构信息
Labcorp Oncology, Durham, NC, 27560, USA.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.
出版信息
Oncol Ther. 2024 Mar;12(1):13-17. doi: 10.1007/s40487-023-00249-0. Epub 2023 Nov 14.
Abstract
摘要
相似文献
1
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Oncol Ther. 2024 Mar;12(1):13-17. doi: 10.1007/s40487-023-00249-0. Epub 2023 Nov 14.
2
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Int J Mol Sci. 2023 May 4;24(9):8206. doi: 10.3390/ijms24098206.
3
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Clin Cancer Res. 2020 Feb 15;26(4):775-786. doi: 10.1158/1078-0432.CCR-18-1976. Epub 2019 Oct 3.
4
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
Ann Transl Med. 2014 Dec;2(12):122. doi: 10.3978/j.issn.2305-5839.2014.08.13.
5
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Breast Cancer Res. 2021 Aug 11;23(1):84. doi: 10.1186/s13058-021-01459-y.
6
[HER2-low breast cancer - A new entity that could expand possibilities of getting treatment].
Lakartidningen. 2022 Nov 17;119:22093.
7
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Clin Cancer Res. 2014 Jan 1;20(1):15-20. doi: 10.1158/1078-0432.CCR-13-0541. Epub 2013 Oct 17.
8
Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer.
Front Endocrinol (Lausanne). 2023 Oct 10;14:1270453. doi: 10.3389/fendo.2023.1270453. eCollection 2023.
9
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.
Pharmgenomics Pers Med. 2014 Oct 15;7:329-38. doi: 10.2147/PGPM.S47524. eCollection 2014.
10
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
Target Oncol. 2023 May;18(3):313-319. doi: 10.1007/s11523-023-00964-8. Epub 2023 May 3.
引用本文的文献
1
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.
NPJ Breast Cancer. 2025 Feb 20;11(1):19. doi: 10.1038/s41523-025-00723-0.
本文引用的文献
1
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Nat Med. 2023 Aug;29(8):2110-2120. doi: 10.1038/s41591-023-02478-2. Epub 2023 Jul 24.
2
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
J Clin Oncol. 2023 Aug 1;41(22):3867-3872. doi: 10.1200/JCO.22.02864. Epub 2023 Jun 7.
3
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Ann Oncol. 2023 Aug;34(8):645-659. doi: 10.1016/j.annonc.2023.05.008. Epub 2023 Jun 1.
4
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Int J Mol Sci. 2023 May 4;24(9):8206. doi: 10.3390/ijms24098206.
5
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
Target Oncol. 2023 May;18(3):313-319. doi: 10.1007/s11523-023-00964-8. Epub 2023 May 3.
6
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
JAMA Oncol. 2023 Apr 1;9(4):500-510. doi: 10.1001/jamaoncol.2022.7476.
7
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
JAMA Oncol. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286.
8
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
9
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
JAMA Oncol. 2022 Apr 1;8(4):1-4. doi: 10.1001/jamaoncol.2021.7239.
10
Evolution of low HER2 expression between early and advanced-stage breast cancer.
Eur J Cancer. 2022 Mar;163:35-43. doi: 10.1016/j.ejca.2021.12.022. Epub 2022 Jan 13.
Zotero 插件